Antony J. Sheehan, PhD

TGR BioSciences Pty Ltd (Abcam Company), South Australia, Australia

A commercially minded biotechnology scientist with over 15 years industry experience in the development/commercialization of immunoassay screening technologies/products for academics, pharma/biotech's and diagnostics. Founder of TGR’s CaptSure immunoassay technology (formal IP) which underpins TGR’s internal R&D/Manufacturing activities and external commercialization activities. Lead the team in South Australia and its ongoing investment in the AlphaLISA SureFire Ultra platform for measurement of high value drug targets (kinases) for pharma/biotech drug discovery programs. Manage the commercialization/licensing opportunities linked to TGR’s core IP and its various industry collaborations.

Disclosure information not submitted.

Presentation(s):

• Discovery of BDK inhibitors with stabilizing or destabilizing pharmacology (Allan Reyes) AlphaLISA SureFire technology for the elucidation of cellular signaling cascades and mechanism of action in drug discovery programs (Antony Sheehan)

  Monday, February 5, 2024
  2:00 PM – 3:00 PM EST

• Powering high-throughput ELISA assays with recombinant technology

  Tuesday, February 6, 2024
  12:00 PM – 1:00 PM EST